Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate (NASDAQ:SAVA)
seekingalpha.com
finance
2022-05-31 19:37:35

John M Lund Photography Inc/DigitalVision via Getty Images After the storm, the calm. Cassava Sciences (NASDAQ:SAVA) has taken investors on a rollercoaster ride across the past two years, ever since the company - developing a novel drug, Simufilam, to treat Alzheimer's Disease ("AD") - looked doomed after failing a Phase 2b trial in May 2020. That trial failure can be considered the turning point for Cassava and the beginning of its wild share price fluctuations. In the past year alone, Cassava stock has traded as high as $135 and sunk as low as $18.
